Charles Schwab Investment Management Inc. Grows Position in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Charles Schwab Investment Management Inc. increased its position in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 0.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 149,206 shares of the company’s stock after purchasing an additional 1,092 shares during the period. Charles Schwab Investment Management Inc. owned 0.24% of Pulse Biosciences worth $2,598,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in shares of Pulse Biosciences during the 4th quarter valued at $193,000. Oppenheimer & Co. Inc. bought a new stake in Pulse Biosciences during the fourth quarter worth about $311,000. Franklin Resources Inc. purchased a new stake in Pulse Biosciences in the third quarter worth about $378,000. Barclays PLC increased its stake in shares of Pulse Biosciences by 361.4% during the third quarter. Barclays PLC now owns 30,306 shares of the company’s stock valued at $530,000 after purchasing an additional 23,738 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in shares of Pulse Biosciences during the third quarter valued at approximately $588,000. Institutional investors own 76.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Pulse Biosciences to a “sell” rating in a research report on Thursday, January 2nd.

Pulse Biosciences Stock Performance

Shares of NASDAQ:PLSE opened at $15.66 on Friday. The business has a fifty day moving average price of $18.83 and a 200-day moving average price of $18.17. Pulse Biosciences, Inc. has a 1-year low of $6.60 and a 1-year high of $25.00.

Pulse Biosciences Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.